A Cross-sectional Study Among Healthcare Professionals in Canada to Assess Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/37710
• EU PAS number:
  EUPAS36083
• Study ID:
  37710
• Official title and acronym:
  A Cross-sectional Study Among Healthcare Professionals in Canada to Assess Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures
• DARWIN EU® study:
  No
• Study countries:
  Canada
• Study description:
  This Cross-sectional study will assess Healthcare Professional's (HCPs) receipt and use of the Fibristal aRMMs, and knowledge of the key messages included in the materials developed as well as information in the December 2018 updated Canadian Product Monograph (CPM) for Fibristal. This study was cancelled before any data collection due to business reasons.
• Study status:
  Finalised

Research institutions and networks

Institutions

ICON Commercialisation & Outcomes

Germany

Ireland

Study timelines

Date when funding contract was signed

Planned: 21/04/2019

Actual: 21/04/2019

Study start date

Planned: 30/09/2020

Actual: 28/09/2020

Date of final study report

Planned: 30/06/2021

Actual: 28/09/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Allergan

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

CMO-EPI-WH-0618